GLP-1s, Love, and the Price of a New Face
A closer look at GLP-1s, from women's job prospects to the business of putting fat back.
Beyond the Scale | PoundsPunch Periodical | September 2026
Plastic surgeon Michael Dobryansky hears a particular complaint from patients after substantial weight loss: "My body looks better, but my face looks older."
He described it in an interview published by the American Society of Plastic Surgeons. Some patients want a little fat put back into their cheeks or temples, even though they have spent months trying to lose it elsewhere.
That request helps explain why facial fat grafting is attracting attention. The society's latest figures, released in September, show a sharp rise in the procedure. Elsewhere, researchers are looking at alcohol consumption and women's job prospects, while retailers reconsider which clothing sizes to stock. Here are four developments worth a closer look.
GLP-1s at the job interview
We covered the relationship findings in July. The employment result from the same study is worth returning to, because it raises an awkward question about who gets a chance in the first place.
In a June working paper, economist Rebecca Diamond compared women starting GLP-1s for weight loss with women who wanted treatment but had not started. Among those initially not working, she estimated an employment gain of 27 percentage points relative to the comparison group after six or more quarters, or about 18 months. Initially single women showed a 29-point increase in marriage or living with a partner.
The pattern mattered as much as the size of those estimates. Women already employed did not show upward job mobility, and existing couples did not show more breakups. Diamond's interpretation is that weight may matter particularly when people are meeting a prospective employer or partner for the first time.
That doesn't establish that appearance explains the difference. This was not a randomized trial, and matching women with similar backgrounds cannot eliminate every other explanation. Still, it gives researchers a reason to examine first impressions rather than assuming that any improvement must come from better health or greater confidence.
The findings aren't universal. A separate working paper by Robert Kaestner and Cuiping Schiman, studying adults with diabetes, found no meaningful employment or marriage gains associated with GLP-1 use. These were different patients using the drugs in a different setting, so the two studies are not answering quite the same question.
Putting some of the fat back
Facial fat grafting was the fastest-growing procedure in the American Society of Plastic Surgeons' latest report, up 39% in 2025. Separately, 82% of its member surgeons reported receiving consultation requests related to GLP-1 use.
The report does not tell us how much of the increase in grafting came from GLP-1 patients. And that 82% measures surgeons receiving requests, not patients needing surgery. But it does show how often the subject is coming up in plastic-surgery offices.
The complaint Dobryansky described is easy to understand. Substantial weight loss can leave cheeks and temples looking hollow. The label "Ozempic face" has caught on, although the same changes can follow weight loss without medication. Replacing a little fullness is different from trying to make a face smaller, and it is not the same operation as a facelift.
Fat grafting and facelifts: the difference
Procedure | What it addresses |
Facial fat grafting | Lost fullness: transfers the patient's own fat into selected facial areas. |
Facelift | Sagging: repositions facial tissue and removes excess skin where appropriate. |
The procedures may be combined when someone has both lost volume and sagging tissue. Sources: ASPS on fat grafting and facelifts.
There is a practical catch: transferred fat can still grow or shrink as weight changes. In the ASPS interview, Dobryansky advised waiting until weight is stable or nearly stable and having a long-term plan for GLP-1 treatment. A consultation should cover that timing, the risks and the possibility of needing further work.
For a patient budgeting for weight-loss treatment, this is a possible extra expense, not an inevitable next step. For a clinic, it is a reason to pay attention to the drugs even if the clinic never prescribes them.
A different sort of drinking study
When we wrote about GLP-1s and cravings in May, alcohol was one of the more intriguing areas of research. A newer trial, published online in July and in the September issue of the American Journal of Psychiatry, takes the question to people actively seeking help for a drinking problem.
Researchers assigned 50 adults with moderate-to-severe alcohol use disorder to oral semaglutide or a placebo for eight weeks. Those taking semaglutide had fewer heavy-drinking days. They also reported less craving in everyday life.
The results were mixed, however. Semaglutide did not significantly reduce craving in the laboratory test chosen as the main outcome, or average drinks per calendar day. The researchers saw enough promise to call for further development, but this was not an unqualified success.
One useful detail: weight loss did not differ significantly between the groups. That suggests the drinking findings deserve investigation in their own right, rather than being treated simply as a consequence of people getting smaller. The dose and treatment duration needed to sustain any benefit remain unknown.
Eight weeks cannot tell us whether an improvement lasts for years or survives stopping treatment. Semaglutide remains an experimental approach to alcohol use disorder. There are already established treatment options, including counseling and approved medicines, for people who want help now.
What happens to the larger sizes?
A shopper doesn't have to take a weight-loss drug to be affected by a retailer's assumptions about one. If a shop stops carrying your size, the reason makes little difference when you need a dress.
An analysis by retail-data firm EDITED found that H&M in the U.S. had removed 3XL and 4XL from the dress assortment it examined. That is a finding about the range tracked by the firm, not proof that every larger size has vanished from every H&M store.
Walmart went the other way. Extended sizes rose from about 24% to 33% of the in-stock women's dress sizes in EDITED's comparison. These are measures of what was available, not sales figures, and they don't tell us whether the customers take GLP-1s.
The contrast is a useful check on claims that weight-loss drugs are making plus-size fashion disappear. Retailers are making different bets about their customers. The figures alone cannot separate the effect of medication from pricing decisions, fashion trends or a brand's choice of audience.
Some changes are less drastic than dropping a size. EDITED also noted growth in adjustable waistbands, belted styles and hidden drawstrings. Those details let clothes accommodate a changing body rather than fit at only one point along the way.
For someone still losing weight, that may be a more useful purchase than another dress that fits perfectly for a month. It would also be a welcome outcome of the GLP-1 boom: clothes that adapt to the customer, rather than another instruction for the customer to adapt.
Sources linked throughout. Research and reports checked September 27, 2026. The surgeon's remarks are from an ASPS-published interview, not an interview conducted by PoundsPunch.
Comments